	Bold Therapeutics, a clinical-stage biopharmaceutical company based in Canada, announced on March 27, 2020 that its lead drug BOLD-100 may have the potential to be used as a novel antiviral agent against COVID-19.

	According to a company press release, the drug is an anti-resistance ruthenium-based small-molecule drug that restrains stress-induced upregulation of GRP78. Currently, the company is developing the drug in combination with FOLFOX and other anti-cancer agents for the treatment of gastrointestinal cancers but, after a 

 pinpointed GRP78 as a potential binding site for COVID-19, the company decided to explore its options, the press release said.

	The company is currently seeking interest from companies who have the skill and means to rapidly advance BOLD-100 for the treatment of COVID-19.  

Bio/Pharma News

COVID-19 Update

PharmTech News

The company is currently seeking interest from companies who have the skill and means to rapidly advance BOLD-100 for the treatment of COVID-19.  